Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection

Hepatology

Volumn 34, Issue 3, 2001, Pages 578-582

  de Man, Robert A ^a   Wolters, Leonieke M M ^a   Nevens, Frederik ^b   Chua, David ^c   Sherman, Morris ^d   Lai, Cing L ^e   Gadano, Adrian ^f   Lee, Youngmee ^g   Mazzotta, Fransesco ^h   Thomas, Neil ⁱ   DeHertogh, Deborah ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Research Concepts   (United States)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e QUEEN MARY HOSPITAL   (Hong Kong)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g BOSTON MEDICAL CENTER   (United States)

^h SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; INTERFERON; LAMIVUDINE; PLACEBO; POLYCLONAL ANTIBODY; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0034867425     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.26815     Document Type: Article

References (25)

1. Hepatitis B virus infection
2. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials
3. Fatal decompensation of chronic viral hepatitis associated with alpha-interferon treatment
4. Lamivudine as initial treatment for chronic hepatitis B in the United States
5. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
6. A one-year trial of lamivudine for chronic hepatitis B
7. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
8. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
9. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
10. Seroconversion after lamivudine treatment is not durable in chronic hepatitis B
11. Hepatitis B virus reactivation after lamivudine discontinuation
12. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis B virus
13. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2′-3′-dideoxy-3′-thiacytidine on the replication of hepatitis B virus and accumulation of covalently closed circular DNA
14. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
15. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
16. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
17. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model for hepatitis B infection
18. Maintenance of viral suppression in chronically infected woodchucks with weekly dosing of BMS-200475
19. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
20. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients
21. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection
22. Mammalian DNA polymerases α, β, γ, δ, and ε incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate
23. Mitochondrial injury. Lessons from the fialuridine trial
24. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B